UroOncology Laboratory - LICR Melbourne Centre for Clinical Sciences

MELBOURNE CENTRE FOR CLINICAL SCIENCES

Research > UroOncology Lab

Uro-Oncology Lab

The Uro-Oncology Laboratory is studying cancers related to the urinary system: kidney, prostate and bladder cancers. These cancers are highly prevalent in Australia, but current treatments are not ideal. As we understand the basic biology of these cancers more clearly, we are discovering new potential targets for treatment.

The LICR Uro-Oncology Laboratory, which has very close interactions with the surgeons and cancer specialists who care for these patients, will examine the processes underlying the causes and growth of these cancers.

Research in our laboratory will specifically concentrate on the nature of stem cells in these cancers, how these cancers use signalling pathways within the cell, how they interact with their environment, how they are recognised by and interact with the immune system, and how these processes correlate with the clinical outcomes and responses to treatment we observe in these patients.

These research projects will involve collaboration with the other research groups within the Melbourne Centre, other programs within LICR, and other Australian and international collaborators.

Publications

1.Davis, I.D., Brady, B., Kefford, R.F., Millward, M., Cebon, J., Skrumsager, B.K., Mouritzen, U., Hansen, L.T., Skak, K., Lundsgaard, D., Frederiksen, K.S., Kristjansen, P.E., and Mcarthur, G., Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clin Cancer Res, 2009.

2. Kelly, M.P., Lee, S.T., Lee, F.T., Smyth, F.E., Davis, I.D., Brechbiel, M.W., and Scott, A.M., Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate, 69(1): p. 92-104 2009.

3. Pezaro, C., Rosenthal, M.A., Gurney, H., Davis, I.D., Underhill, C., Boyer, M.J., Kotasek, D., Solomon, B., and Toner, G.C., An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. Am J Clin Oncol, 2009.

4. Davis, I.D. and Desai, J., Clinical use of therapies targeting tumor vasculature and stroma. Curr Cancer Drug Targets, 8(6): p. 498-508 2008.

5. Grossmann, M., Premaratne, E., Desai, J., and Davis, I.D., Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf), 69: p. 669-672 2008.

6. Nicholaou, T., Wong, R., and Davis, I.D., Tumour lysis syndrome in a patient with renal cell carcinoma treated with sunitinib malate. The Lancet, 369: p. 1923-1924 2007.

Click Here For More

Research Links

	Overview
	Tumour Targeting Laboratory
	Cancer Vaccine Laboratory
	T Cell Laboratory
	Uro-Oncology Laboratory
	Oncogenic Transcription Laboratory
	Joint Austin Ludwig Oncology Unit
	Centre for PET
	Key Technologies

Uro-Oncology Lab Staff

Laboratory Head

A/Prof. Ian Davis

Staff Directory

Ian Davis - Laboratory Head
Pavel Sluka - Postdoctoral Fellow
Lekshmy Shanker - Project Co-ordinator
Genevieve Whitty - Research Assistant
Niero Rajarubendra - M.D. Student
Carmel Pezaro - M.D. Student
Phillip Tan - M.D. Student

Of Note

Grants

Ian Davis
Victorian Cancer Agency Clinician Researcher Fellowship 2007-2009
Victorian Cancer Agency Tumour Stream Research Grant 2008-2011
Victorian Cancer Agency Cancer Clinical Trials Grant 2008-2011
Cancer Australia Priority Driven Cancer Research Scheme 2008-2011
ANZ Trustees Medical Research and Technology in Victoria- James and Vera Lawson Trust Equipment Grant 2009

Niero Rajarubendra
Cancer Research Institute Scholarship 2007-2009

Carmel Pezaro
RACP Arnott Research Entry Scholarship 2010